• access to vast treatment-naïve patient populations
• High prevalence of metabolic diseases, cancer and infectious diseases

 
India is the world’s second most populated country with 1.3 billion people. Over the past decade, India has implemented an internationally recognized regulatory system making it increasingly attractive for the clinical trial sector.
India’s healthcare system is developing rapidly and expanding to cover an increasing percentage of the population. Growth in the pharmaceutical industry is being driven by epidemiological factors, increasing affordability and enhanced accessibility.

India has high levels of wage inequity, so while rural areas continue to struggle with infectious diseases and sanitation, wealthy urban areas are seeing an increase in developed nations’ lifestyle diseases including diabetes and heart disease.

Novotech has established strong clinical teams in India with deep local knowledge to deliver quality CRO services to biotechnology companies. In addition, it has partnered with key specialist hospital and research facilities giving Novotech clients direct access to the most active and reputable KOLs, PIs and sites to facilitate study start-up and patient recruitment.

Novotech has grown its employee base by over +65% in India in 2019 to accommodate the growing biotechnology clinical activity demand.
With a high prevalence of cancers and communicable diseases, biotechnology companies are looking to India for oncology, immuno-oncology, infectious diseases and vaccines studies.
 
Novotech estimates the recent clinical activity growth of biotechnology companies in India to be about +70% for oncology and infectious diseases studies.